Gelteq (GELS) investor relations material

Technology platform and scientific advancements

• Developed a proprietary gel-based platform to improve drug absorption, solubility, and precise dosing for both human and animal applications.

• Holds multiple patent families covering the technology's application, with ongoing expansion of IP globally.

• Gel base is non-calorific, allergen-free, and adaptable for various religious and dietary needs.

• Demonstrated 40% improved bioavailability for water-soluble drugs and 300% improved first-hour absorption for oil-soluble drugs.

• Platform supports multiple dosage forms, including gels, pouches, syringes, and gummies.

Clinical and commercial progress

• Completed large-scale palatability trials in dogs, showing over 95% preference for gel-based products.

• Preclinical diabetes study and veterinary clinical trial completed, with results pending release.

• Human clinical trial is set to begin next quarter, targeting a late 2026 or early 2027 submission.

• Commercial manufacturing underway, with products being delivered to an East Asian nutritional client.

• Established a center of excellence in China to accelerate product development and out-licensing.

Market strategy and business model

• Focuses on licensing technology to pharmaceutical companies, with revenue from R&D fees, manufacturing, and royalties.

• Targets drugs with poor solubility and patient compliance challenges, addressing both human and animal health markets.

• Platform extends patent life cycles and helps defend against generics by offering improved bioavailability and new dosage forms.

• Recent AUD 3.5 million debt financing secured to support commercialization and expansion.

• Multiple clinical and regulatory milestones expected in the coming months, including FDA submissions and trial results.